Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 results
Biohaven started a pivotal Phase 3 trial for BHV-1300 in Graves' disease and reported new biomarker data across its degrader and epilepsy programs, with cash of $270.5 million as of June 30, 2026.
Biohaven Ltd. reported second quarter 2026 financial results and business updates on August 10, 2026. The company said it initiated a pivotal trial of BHV-1300 in Graves' disease based on Phase 1b results, and expects to pursue additional follow-on studies in other autoimmune diseases1. That Phase 3 study is a randomized, double-blind, placebo-controlled study in approximately 300 adults with Graves' hyperthyroidism evaluating normalization of T3, T4, and TSH at 26 weeks absent an antithyroid drug1.
In the underlying Phase 1b data presented in May 2026, weekly administration of BHV-1300 1000 mg subcutaneously achieved mean reductions of pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12 in patients with Graves' hyperthyroidism1.
For BHV-1400 in IgA nephropathy, Biohaven reported that the drug administered subcutaneously achieved mean reductions of pathogenic Gd-IgA1 of greater than 60% within 48 hours and approximately 70% within the first month of dosing1, and said a pivotal study is expected to initiate in 2H 20261.
In epilepsy, the company said topline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 20261. Earlier proof-of-concept data showed the median time to the second generalized tonic-clonic seizure was 141 days with opakalim versus 47 days with placebo, with 33% of treated participants completing the 24-week double-blind period without a second seizure1.
In oncology, Biohaven announced a new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with Libtayo1, which the company said builds upon the existing clinical supply agreement between Biohaven and Regeneron for BHV-1510, a next-generation TROP2-directed ADC1.
Elsewhere, patient enrollment is complete in the ongoing Phase 2 study of taldefgrobep alfa in obesity, with topline data expected during 2H 20261, and enrollment continues in the global Phase 2/3 study of BHV-8000 for early Parkinson's disease.
On finances, cash, cash equivalents, marketable securities and restricted cash as of June 30, 2026, totaled approximately $270.5 million1. Biohaven reported a net loss for the three months ended June 30, 2026 of $137.3 million, or $0.91 per share, compared to $198.1 million, or $1.94 per share, for the same period in 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.